Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-01

FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for INVOKAMET, the fixed-dose combination of canagliflozin and metformin hydrochloride, submitted by Janssen Pharmaceuti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Invokamet (canagliflozin and metformin hydrochloride)

Snippet

SUPPL AP for INVOKAMET (CANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)